Long-term health risks linger for severe COVID-19 patients three years after hospitalization

FHS
June 3, 2024
2:23 am

Three years after severe COVID-19 hospitalization, significant risks of mortality and long-term symptoms persist, impacting overall health and quality of life.

Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran – Pharmaceutical Technology

RNAi therapeutic, vutrisiran is FDA approved for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTR) in adults and is sold under the brand name

June 24, 2024

IU researchers receive $5 million grant to improve care for adolescents with opioid use disorder

IU School of Medicine researchers are taking steps to improve the accessibility and quality of care for adolescents experiencing opioid use disorder (OUD) and other

November 14, 2023

Combining JAK inhibitors with checkpoint inhibitors improves cancer immunotherapy response

Because not all cancer patients respond to a leading type of cancer immunotherapy drug, known as an immune checkpoint inhibitor, scientists explored whether adding janus

June 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.